Retatrutide

A novel triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Developed by Eli Lilly, retatrutide has produced the highest weight loss ever recorded in an obesity clinical trial, representing a potential paradigm shift in pharmacological weight management.

• GLP-1 receptor agonism suppresses appetite and enhances insulin secretion
• GIP receptor agonism improves fat metabolism and insulin sensitivity
• Glucagon receptor agonism increases energy expenditure and hepatic fat oxidation
• Triple agonism produces synergistic effects on weight and metabolism

• Personal or family history of medullary thyroid carcinoma
• MEN2 syndrome
• Severe hepatic impairment
• History of pancreatitis
• Pregnancy or breastfeeding

Store at 2–8°C (36–46°F), protected from light. Detailed storage guidelines pending full regulatory approval.

Phase 2 results published in NEJM showed retatrutide 12 mg produced 24.2% mean weight loss at 48 weeks, with 26% of participants losing over 30% of body weight — the highest ever reported in a clinical trial. A sub-study demonstrated 86% relative reduction in liver fat. Multiple Phase 3 trials (TRIUMPH program) are underway across obesity, type 2 diabetes, and MASH indications. Eli Lilly anticipates potential FDA submission by 2026.